SEQUENCE LISTING

```
<110> BIOMIRA INC. et al.
<120> IMMUNOSTIMULATORY, COVALENTLY LIPIDATED OIGONUCLEOTIDES
<130> JIANG=4A PCT
<140> PCT/CA03/00135
<141> 2003-02-04
<150> 60/353,195
<151> 2002-02-04
<160> 12
<170> PatentIn version 3.2
<210> 1
<211> 10
<212> DNA
<213> Artificial
<220>
<223> 128H
<400> 1
                                                                      10
cacacgtgtg
<210> 2
<211> 25
<212> PRT
<213> Artificial
<220>
<223> Fig. 17 BP1-148
<400> 2
Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg
Pro Ala Pro Gly Ser Thr Ala Pro Pro
            20
<210> 3
<211> 20
<212> DNA
<213> Artificial
<220>
<223> activating sequence
<400> 3
```

```
ggtgcatcga tgcagggggg
<210> 4
<211> 10
<212> PRT
<213> leishmani major
<400> 4
Glu Ala Glu Glu Ala Ala Arg Leu Gln Ala
<210> 5
<211> 25
<212> PRT
<213> Artificial
<220>
<223> MUC1 repeat consensus sequence
<400> 5
Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala Gln Thr Ala His Gly Val
                                   10
Thr Ser Ala Pro Asp Glu Thr Ser Arg
           20
<210> 6
<211> 12
<212> PRT
<213> Artificial
<220>
<223> MUC1 fragment
<400> 6
Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr
<210> 7
<211> 9
<212> PRT
<213> Artificial
```

<220>

<400> 7

<223> MUC1 fragment

Thr Leu Ala Pro Ala Thr Glu Pro Ala

20

```
1
              5
<210> 8
<211> 9
<212> PRT
<213> Artificial
<220>
<223> MUC1 fragment
<400> 8
Ala Leu Gly Ser Thr Ala Pro Pro Val
1 5
<210> 9
<211> 9
<212> PRT
<213> Artificial
<220>
<223> MUC1 fragment
<400> 9
Phe Leu Ser Phe His Ile Ser Asn Leu
1 5
<210> 10
<211> 20
<212> PRT
<213> Artificial
<220>
<223> MUC1 repeat
<400> 10
Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala
              5
Pro Pro Ala His
<210> 11
<211> 28
<212> PRT
<213> Artificial
<220>
<223> Fig. 17, intermediate
```